SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-291535
Filing Date
2021-10-05
Accepted
2021-10-05 07:15:41
Documents
13
Period of Report
2021-10-05
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d226125d8k.htm   iXBRL 8-K 25267
2 EX-99.1 d226125dex991.htm EX-99.1 17567
  Complete submission text file 0001193125-21-291535.txt   175646

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tsha-20211005.xsd EX-101.SCH 2882
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20211005_lab.xml EX-101.LAB 18887
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20211005_pre.xml EX-101.PRE 11853
6 EXTRACTED XBRL INSTANCE DOCUMENT d226125d8k_htm.xml XML 3474
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 211305139
SIC: 2836 Biological Products, (No Diagnostic Substances)